BIGBEAR
PHARMACEUTICALS
Repotrectinib potently and selectively inhibits the abnormally activated kinase signaling pathways of ROS1 and NTRK, effectively overcomes resistance mutations to conventional targeted therapies, and exhibits favorable central nervous system penetration.
AuthenticGuaranteeFast DeliveryPrivacy On June 13, 2024, Bristol-Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to repotrectinib fo···【Read More】
Update: 03 Mar,2026Source: Haiou HealthViews: 71
Copyright2024@ BIGBEAR All right reserved BIGBEAR
